---
document_datetime: 2025-11-25 15:03:22
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hympavzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: hympavzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.260739
conversion_datetime: 2025-12-23 23:44:49.348474
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hympavzi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | B.I.a.1 Change in the manufacturer of a | 06/11/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000292758                     | starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted   |            |     |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000294888 | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/09/2025 | N/A |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Variation type II / EMA/VR/0000268024 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to add information regarding thromboembolic events and to add 'thrombosis\" to the list of adverse drug reactions (ADRs) with frequency uncommon                                                                                                                      | 04/09/2025 |     | SmPC, Annex II and PL | Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to add information regarding thromboembolic events and to add 'Thromboembolic events (thrombosis)\" to the list of adverse drug reactions (ADRs) with frequency uncommon based on a review of clinical data, post marketing data and literature. A patient card is also introduced specifically to highlight the risk of thromboembolism. Please refer to Scientific Discussion 'Hympavzi EMA/VR/0000268024' For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|                                       | based on a review of clinical data, post marketing data and literature. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes and corrections to the PI, including Annex II.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |             | Product Characteristics.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|----------------------------|
| Variation type IB / EMA/VR/0000263723 | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 28/04/2025 | SmPC and PL |                            |

<div style=\"page-break-after: always\"></div>

|                            | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted   |             |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| PSUR / EMA/PSUR/0000282253 | - -                                                                                                                                                                                                                       | Maintenance |